Leiomyosarcoma, a cancer of the uterus, can be treated with the chemotherapy drugs gemcitabine and docetaxel. The purpose of this Gynecologic Oncology Group study is to compare treatment with gemcitabine plus docetaxel to gemcitabine plus docetaxel with a third drug called bevacizumab in women with advanced or recurrent leiomyosarcoma. Patients will be randomly assigned to receive one treatment combination or the other.
Bevacizumab is not approved for leiomyosarcoma, but is used to treat advanced colorectal, lung, breast, kidney, and brain cancers. It works by blocking vascular endothelial growth factor (VEGF), a protein that promotes the growth of tumor cells and blood vessels in and around tumors.